ANI Pharmaceuticals completes purchase of Alimera Sciences

ANI Pharmaceuticals completes purchase of Alimera Sciences
ANI Pharmaceuticals falls amid Truist downgrade on delayed Alimera deal close
ANI Pharmaceuticals, Alimera Sciences deal set to close Monday
Alimera Sciences plunges after it sues ANI Pharmaceuticals to close deal
Alimera Sciences leaps on takeover deal by ANI Pharmaceuticals
1.84BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US00182C1036
CUSIP
09065V302
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
20.74
PEG Ratio
1.06
Book Value
26.34
Dividend Share
-
Dividend Yield
-
Earnings Share
3.91
Wall Street Target Price
109.88
EPS Estimate Current Year
9.40
EPS Estimate Next Year
10.61
EPS Estimate Current Quarter
1.2994
EPS Estimate Next Quarter
2.1533
Most Recent Quarter
-
Revenue TTM
923,705,984
Gross Profit TTM
561,851,008
EBITDA
197,379,008
Profit Margin
9.98%
Return On Assets TTM
4.97%
Return On Equity TTM
18.32%
Revenue Per Share TTM
45.325
Qtly Revenue Growth YOY
20.50%
Diluted Eps TTM
3.91
Qtly Earnings Growth YOY
86.10%
Trailing PE
20.74
Forward PE
9
Price Sales TTM
1.9963
Price Book MRQ
3.2794
Enterprise Value Revenue
2
Enterprise Value EBITDA
9
9.12
1.79%15.60
0.97%163.78
0.04%15.64
0.00%30.34
0.00%30.47
0.00%194.60
-8.85%31.34
-3.42%34.19
-0.70%40.41
-0.42%